SoftBank has led a round that took the liquid biopsy system developer's total funding to about $550m, as part of a joint venture agreement between the companies.
Guardant Health, the US-based developer of a liquid biopsy system for cancer detection, raised $360m yesterday in a round led by an unnamed subsidiary of telecommunications firm SoftBank.
The round also featured Singaporean state-owned firm Temasek as well as Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, OrbiMed, 8VC, and funds and accounts managed by T. Rowe Price.
Founded in 2013, Guardant is working on non-invasive cancer diagnostics tests for cancer that utilise digital sequencing technology to provide a detailed picture…
